



## REGENXBIO to Participate in Upcoming Investor Conferences

February 24, 2021 9:05 PM EST

ROCKVILLE, Md., Feb. 24, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following March investor conferences, which will each be held in a virtual meeting format:

**Raymond James 42<sup>nd</sup> Annual Institutional Investors Conference**

**Fireside chat:** Wednesday, March 3, 2021 at 10:50 a.m. ET

**Barclays Global Healthcare Conference**

**Fireside chat:** Tuesday, March 9, 2021 at 4:10 p.m. ET

**Morgan Stanley Virtual Healthcare Corporate Access Day**

**Date:** Tuesday, March 16, 2021

Live webcasts of the Raymond James and Barclays fireside chats can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the webcasts will be available on the same website for approximately 30 days following the presentation.

**About REGENXBIO Inc.**

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV<sup>®</sup> Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

**Contacts:**

Tricia Truehart  
Investor Relations and Corporate Communications  
347-926-7709  
[ttruehart@regenxbio.com](mailto:ttruehart@regenxbio.com)

Investors:  
Brendan Burns, 212-600-1902  
[brendan@argotpartners.com](mailto:brendan@argotpartners.com)

Media:  
David Rosen, 212-600-1902  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301234852.html>

SOURCE REGENXBIO Inc.